Drug intelligence / Profile preview

ramipril + enalapril + captopril + perindopril + lisinopril

Development stage
Discontinued
Lead developer
Hoechst
Modality
Small Molecules
Administration
Oral, Intravenous
01

Overview

This is a combination of five angiotensin-converting enzyme (ACE) inhibitors—ramipril, enalapril, captopril, perindopril, and lisinopril. Each of these drugs individually inhibits the angiotensin-converting enzyme, which reduces the production of angiotensin II. This leads to vasodilation (widening of blood vessels), decreased blood pressure, and reduced workload on the heart. ACE inhibitors are primarily used for treating hypertension (high blood pressure), heart failure, and certain types of chronic kidney disease. The simultaneous use or combination of multiple ACE inhibitors is not standard clinical practice due to increased risk for adverse effects such as hypotension, hyperkalemia (elevated potassium), renal dysfunction, and angioedema[1][2][3][4][5]. There is no evidence supporting additional benefit from combining multiple ACE inhibitors; instead it significantly increases risks[6].

02

Targets

ACE (Angiotensin Converting Enzyme)

Beyond the preview

Go deeper on ramipril + enalapril + captopril + perindopril + lisinopril.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ramipril + enalapril + captopril + perindopril + lisinopril.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call